PRDM6 Polyklonaler Antikörper

PRDM6 Polyklonal Antikörper für WB, ELISA

Wirt / Isotyp

Kaninchen / IgG

Getestete Reaktivität

human

Anwendung

WB, ELISA

Konjugation

Unkonjugiert

Kat-Nr. : 33205-1-AP

Synonyme

EC:2.1.1.361, PFM3, PR domain zinc finger protein 6, PR domain-containing protein 6, Putative histone-lysine N-methyltransferase PRDM6

---

• 

  WB analysis using 33205-1-AP

  Various lysates were subjected to SDS PAGE followed by western blot with 33205-1-AP (PRDM6 antibody) at dilution of 1:3000 incubated at room temperature for 1.5 hours.

---

Geprüfte Anwendungen

• Erfolgreiche Detektion in WB: Jurkat-Zellen, MCF-7-Zellen, MDA-MB-231-Zellen

Empfohlene Verdünnung

• Western Blot (WB): WB : 1:1000-1:6000

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Produktinformation

33205-1-AP bindet in WB, ELISA PRDM6 und zeigt Reaktivität mit human

• Getestete Reaktivität: human
• Wirt / Isotyp: Kaninchen / IgG
• Klonalität: Polyklonal
• Typ: Antikörper
• Immunogen: PRDM6 fusion protein Ag38054
• Vollständiger Name: PR domain containing 6
• Berechnetes Molekulargewicht: 595aa, 64 kDa
• Beobachtetes Molekulargewicht: 75 kDa
• GenBank-Zugangsnummer: NM_001136239
• Gene symbol: PRDM6
• Gene ID (NCBI): 93166
• Konjugation: Unkonjugiert
• Form: Liquid
• Reinigungsmethode: Antigen-Affinitätsreinigung
• Lagerungspuffer: PBS with 0.02% sodium azide and 50% glycerol
• Lagerungsbedingungen: Bei -20°C lagern. Nach dem Versand ein Jahr lang stabil Aliquotieren ist bei -20^oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

PRDM6 is a poorly characterized member of the PRDF1 and RIZ1 homology domain-containing (PRDM) family of transcription factors that possess histone lysine methyltransferase activities through their catalytic SET domain. Based on findings in other species, PRDM6 is currently classified as a pseudo-methyltransferase that may interact with the methyltransferase G9a and corepressors to indirectly affect the methylation status of histone H3 lysine and histone H4 lysine. PRDM6 inhibition may have therapeutic value in PRDM6-expressing medulloblastomas (PMID: 38992221). PRDM6 has one glycosylation modification site.